Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.

Takeshi Yamada, Toshikazu Moriwaki, Kenji Matsuda, Yoshiyuki Yamamoto, Akinori Sugaya, Daisuke Akutsu, Tetsuya Murashita, Shinji Endo, Ichinosuke Hyodo

Division of Gastroenterology, Tsukuba University Hospital, Ibaraki, Japan.

Onkologie 2013

filter terms:

A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated interstitial lung disease (ILD) occurred in approximately 1% (19/1767) of patients, causing death in 36.8% of these cases. We report the case of a 60-year-old Japanese man who developed ILD associated with panitumumab therapy (third-line therapy) for metastatic sigmoid colon cancer involving the liver, lymph nodes, and lungs. 2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, dyspnea, and a fever, and was diagnosed with ILD. Intravenous pulse methylprednisolone treatment led to quick recovery. The patient had some risk factors for ILD associated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. Further studies are required to elucidate the association between anti-EGFR antibodies and ILD. Copyright © 2013 S. Karger AG, Basel.

Citation

Takeshi Yamada, Toshikazu Moriwaki, Kenji Matsuda, Yoshiyuki Yamamoto, Akinori Sugaya, Daisuke Akutsu, Tetsuya Murashita, Shinji Endo, Ichinosuke Hyodo. Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer. Onkologie. 2013;36(4):209-12